Kumar Neil sold $152K of BBIO

Kumar Neil (Chief Executive Officer) sold 2,256 shares of BridgeBio Pharma, Inc. (BBIO) at $67.57 ($0.15M total) on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kumar Neil
Published May 26, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BBIO
Neutral
high confidence
Mentioned
$BBIO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The disclosure provides transparency on executive selling activity but does not include any new business, clinical, regulatory, or financial information that would directly change valuation drivers.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but the 10b5-1 framing reduces the likelihood of a fundamental repricing.

03

What to watch

Insider sales can still be interpreted as a signal if multiple executives sell around the same time, but this article provides only one disclosed transaction.

Relevance 6/10Timing: Immediate (new Form 4 filed today; trading impact typically fades quickly).

Background

The article is an SEC Form 4 insider transaction disclosure for BridgeBio Pharma, Inc. (BBIO).

Company-level read

Ticker impact

$BBIONeutralHigh confidence
Context

BridgeBio CEO Kumar Neil sold $152.4K of BBIO shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment rather than fundamentals.

Evidence & confidence

The filing is a routine Form 4 transaction with a disclosed pre-arranged 10b5-1 plan and no accompanying operational or financial catalyst.

Market effects

Minimal; insider sale without drug/earnings catalysts does not reset sector expectations.

None indicated; US-listed biotech-specific sentiment only.

None indicated; no international deal/regulatory event mentioned.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • BridgeBio Pharma, Inc.

    Subject of the Form 4 insider sale by CEO Kumar Neil.

  • Kumar Neil

    CEO and director who sold 2,256 BBIO shares for ~$152.4K under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.